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Aim: to analyze recurrence patterns and define
predictive factors for locoregional recurrence (LRR) and
subsequent recurrences up to 10 years after the primary
tumor.
Follow-up in the Netherlands from 2012:
Using risk thresholds, follow-up visits can be reallocated
based on risk over the ten years following primary
treatment.
Netherlands Cancer Registry (NCR):
• Women diagnosed in 2003 with primary invasive breast cancer
• No distant metastasis (DM), synchronous or previous tumors
• Curatively treated in NL
Survival analysis: Predictors first, second and third
recurrence
Based on current follow-up: Determination lower risk
threshold and quantiles for intervals.
Predictive factors for first recurrence:
Most important predictors for all types (LRR/second
primary/DM) of second recurrence were tumor size,
surgery type and radiotherapy, with the effect of the last
two reversed compared to the first recurrence.
As an example, three risks groups were made for low
(>50, hormone therapy), medium (<50, hormone
therapy) and high (>50, no hormone therapy) risk.
Intervals and threshold based on 5 visits in 5 year:
Below this hazard, we ‘accept’ the risk.
Given these thresholds, the medium risk group should
receive 2 follow-up visits, and the high 7 during the period
of ten years. The low risk group remained below the
threshold for all the ten years.
This model can be used to identify patients with a low or
high risk to personalize follow-up after breast cancer,
develop a decision support tool and allocate resources
efficiently over the whole follow-up period.
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 Cumulative hazard of complete 
population after 5 years: 0.0448
Equal hazard intervals: 
0.00896 per visit
 N=8,035
Hazard of complete population 
after 5 year: 0.0068
 Lower risk threshold
